药物对比
Tirzepatide vs Canagliflozin
比较Tirzepatide（Mounjaro）与Canagliflozin（Invokana）治疗糖尿病：作用机制、血糖和体重控制的疗效、心血管获益、给药方案和风险。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered for type 2 diabetes patients, especially those with obesity or cardiovascular/kidney disease, deciding between an injectable dual agonist and an oral SGLT2 inhibitor.
结论
Tirzepatide often excels in A1C lowering and weight loss while canagliflozin provides oral convenience plus proven heart and kidney protection, so the better option is highly individualized.
全部药物对比